

Shingrix Vaccine recommended for all adult HSCT recipients

The JCVI has updated its advice to recommend that all HSCT recipients aged 18 or over should be offered the Shingrix vaccine. Clinicians can now prescribe the vaccine to HSCT recipients, in line with the Shingrix label and the new BSBMTCT, CCLG and BIA [consensus statement](#) on the vaccination of HSCT recipients.

The JCVI made its recommendation in response to a joint request from the BSBMTCT and Anthony Nolan highlighting the increased risk of developing shingles (Herpes Zoster) in individuals post-HSCT. We are expecting the JCVI to update the relevant Green Book chapters in due course, however in the meantime a record of the decision is available in the JCVI Varicella Subcommittee minutes [here](#) as well as the main meeting minutes [here](#).

Should any clinicians continue to experience challenges in obtaining access to Shingrix for their patients please inform Thushan de Silva on t.desilva@sheffield.ac.uk.

The BSBMTCT and Anthony Nolan are requesting that the Green Book should explicitly include CAR-T recipients in the recommendation, in the meantime a pragmatic approach would be to include CAR-T recipients in the “HSCT recipient” population. The JCVI has also agreed to consider extending access to Shingrix for other immunosuppressed patients aged 18+ and will be modelling the impact of an extension.

John Snowden, Thushan de Silva, Fiona Dignan, Henny Braund, Antonio Pagliuca, Yasmin Sheikh



saving the lives
of people with
blood cancer